Safinamide mesylate
|
|
|
- CAS-Nr.
- 202825-46-5
- Englisch Name:
- Safinamide mesylate
- Synonyma:
- Safinamide Mesilate;NW 1015;PNU 151774E;Safinamide mesylate;Safinamide Mesyalte;Safinamtde Mesytate;EMD 1195686 Mesylate;PNU-151774E, NW-1015;PNU-151774E,FCE28073;Salfenamide mesylate
- CBNumber:
- CB92510036
- Summenformel:
- C17H19FN2O2.CH4O3S
- Molgewicht:
- 398.4490232
- MOL-Datei:
- 202825-46-5.mol
|
Safinamide mesylate Eigenschaften
- Schmelzpunkt:
- 210° (dec)
- alpha
- D25 +12.9° (c = 1.1% in 98% acetic acid)
- storage temp.
- 2-8°C
- Löslichkeit
- H2O: ≥15mg/mL
- Aggregatzustand
- powder
- Farbe
- white to tan
- Optische Aktivität
- [α]/D +9.5 to +14°, c = 1 (95% acetic acid)
Safinamide mesylate Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Safinamide
methanesulfonate was approved in February 2015 by the
EMA for the treatment of mid- to late-stage fluctuating
Parkinson’s disease. This approval included use of the drug as
an add-on therapy for use with levodopa, either alone or in
combination with other existing therapies for Parkinson’s
disease.51 Safinamide methanesulfonate, an oral α-aminoamide
originally discovered by Farmitalia Carlo Erba and later
developed by Newron/Zambon, functions as a highly selective
and reversible inhibitor of MAO-B, leading to increased levels
of dopamine and subsequent improvement in the motor
symptoms of Parkinson’s disease, side effects that often result
from use of other traditional treatments relying on dopamine
replacement therapy.
Verwenden
Safinamide mesylate salt has been used as a reference drug to study its inhibitory effect on human monoamine oxidases (hMAO-A and hMAO-B).
Mechanism of action
Safinamide employs several mechanisms of action, functioning
as both a dopaminergic agent through inhibition of MAO-B as
well as a nondopaminergic agent via selective calcium and
sodium channel modulation, leading to inhibition of glutamate
release. At least one of several clinical studies of patients
with mid- to late-stage Parkinson’s disease showed increased
daily ON time (periods of symptom control) without
accompanying motor complications (dyskinesias) upon treatment
with safinamide, while studies of early stage Parkinson’s
disease patients treated with this drug showed significantly
improved motor symptoms during the 18-month study.
Additionally, safinamide is chemically and metabolically
stable, is well tolerated in patients, and has not exhibited
serious adverse effects even upon treatment at higher dosage
ranges.
Nebenwirkungen
Common adverse events in clinical trials (in more than 1% of people) included nausea, dizziness, tiredness, sleeplessness, or thostatic hypotension (low blood pressure) and headache. There was no significant difference in the occurrence of these effects between safinamide and placebo.
Safinamide mesylate Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Safinamide mesylate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 236)Lieferanten
- (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide methanesulfonate
- Safinamide mesylate
- EMD 1195686 Mesylate
- NW 1015
- PNU 151774E
- SafinaMide Methanesulfonate
- PNU-151774E,FCE28073
- (S)-(+)-2-[[4-(3-Fluorobenzoxy)benzyl]amino]propanamide
- PNU-151774E, NW-1015
- Safinamide mesylate salt
- SafinaMide Mesylate(FCE28073)
- Safinamide mesylate, >=99%
- 2(S)-[4-(3-Fluorobenzyloxy)benzylamino]propionamide methanesulfonate
- Safinamide Mesyalte
- Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, methanesulfonate (1:1)
- Safinamidemesylatesal
- Safinamide mesylate USP/EP/BP
- 2(S)-[4-(3-Fluorobenzyloxy)benzylamino]propionamide methanes...
- Salfenamide mesulfonate
- Safinamide Mesilate
- Propanamide,2-[[[4-[(3-fluorophenyl)methoxy]- phenyl]methyl]amino]-,(2S)-,monomethanesulfonate
- S819080 Safinamide Mesylate
- Haloxyfop Impurity 8 ((R)-Clodinafop)
- Salfenamide mesylate
- Safinamtde Mesytate
- 202825-46-5
- C17H19FN2O2CH4O3S
- Inhibitor
- Inhibitors
- API
- chemical
- 202825-46-5
